A third member of a panel of outside advisers to the U.S. Food and Drug Administration has resigned in protest over the agency’s decision to approve Biogen Inc’s (BIIB.O) Alzheimer’s disease treatment despite the committee’s recommendation against doing so.
Flagship Pioneering unveiled Laronde, a platform company developing Endless RNA™ (eRNA), a novel, engineered form of RNA that can be programmed to express therapeutic proteins inside the body. Flagship initially committed $50 million to support the development of Laronde’s platform and initial pipeline of new medicines.
Fresh off global validation of their Covid-19 vaccine’s extraordinary effectiveness, Russian developers are in talks with China’s CanSino Biologics Inc. to test a combined regimen of their shots to better protect against new virus strains, according to people with knowledge of the matter.
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the company is discontinuing development of its SARS-CoV-2/COVID-19 vaccine candidates, V590 and V591, and plans to focus its SARS-CoV-2/COVID-19 research strategy and production capabilities on advancing two therapeutic candidates, MK-4482 and MK-7110.
Cyber-security researchers from Ben-Gurion University of the Negev recently discovered a computer attack that could allow hackers to remotely trick laboratory scientists into creating toxins and viruses.
GRAIL, Inc., a healthcare company whose mission is to detect cancer early, when it can be cured, today announced a partnership with the United Kingdom’s (UK) National Health Service (NHS) to help transform cancer outcomes by making GRAIL’s multi-cancer early detection blood test, Galleri™, available to UK patients starting in 2021.